Molecular signature and assay for fluoroquinoline resistance in bacillus anthracis
OwnerPaul S. Keim, Talima Pearson +2inventors
InventorsPaul S. Keim, Talima Pearson, Lance B. Price, Joseph D. Bush
Life of this patent
Estimating the term…
Loading patent…
OwnerPaul S. Keim, Talima Pearson +2inventors
InventorsPaul S. Keim, Talima Pearson, Lance B. Price, Joseph D. Bush
Estimating the term…
The preferred therapeutic for human anthrax infections are therapeutics from the fluoroquinolone class, in particular, Ciprofloxacin (CIP). This invention discloses the molecular basis for fluoroquinolone (CEP in particular) action and provides the molecular signatures which form the basis of diagnostic assays. This invention further discloses nucleotide signatures associated with CIP-resistance are useful in diagnostic tests to rapidly identify CIP resistant B. anthracis and to infer the level of resistance of these mutant strains. According to this invention, the diagnostic potential of the molecular signatures is illustrated using a primer extension assay. Further, PCR and extension primers which allow the detection of these signatures are disclosed.
An isolated oligonucleotide comprising at least 12 consecutive nucleotides of a nucleic acid sequence selected from the group of consisting of SEQ ID NO:
A pair of oligonucleotide primers selected from the group of oligonucleotide pairs consisting of:
An oligonucleotide primer selected from the group consisting of:
Dependencies are inferred from the claim text.